Bertocil

Quick links to important sections

Bertocil

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bertocil

Quick Facts

Property Description
Active ingredient Betaxolol
Form Ophthalmic solution (Eye drops)
Pharmacological class Beta-adrenergic receptor antagonist (Beta-blocker)
General purpose Lowers elevated intraocular pressure
Origin Synthetic compound

What is Bertocil and Its Primary Classification?

Bertocil is a prescription ophthalmic solution (eye drops) whose medicinal identity is defined by its active ingredient, Betaxolol. This medicine is a synthetic compound classified pharmacologically as a Beta-adrenergic receptor antagonist, commonly known as a Beta-blocker (β-blocker). Pharmacological studies have clinically recognized Betaxolol as a cardioselective β₁-antagonist, meaning it primarily blocks receptors found in the heart and other tissues, a feature that distinguishes it from non-selective β-blockers used ophthalmologically. This specific selectivity is a differentiating factor, marking it as a distinct option within the class of eye pressure-reducing agents.


Composition and Type of Application

Bertocil is a single-ingredient product where the active agent, Betaxolol hydrochloride, is dissolved within a sterile, aqueous solution which acts as the base vehicle. This formulation is explicitly designed for topical application directly to the ocular surface, contrasting with systemic (oral) medications containing the same active substance. Emphasizing its identity as an ophthalmic solution confirms that its entire design, from composition to route of administration, is optimized for localized action within the eye. Its use is typical in managing conditions characterized by chronic, elevated internal eye pressure.


What is the General Purpose of Bertocil?

The general purpose of Bertocil is to act as a pressure-regulating agent for the eye, specifically designed to address elevated internal pressure. This is achieved through its primary mechanism of reducing the rate at which aqueous humor—the internal fluid that maintains pressure within the eyeball—is produced. This class of agents reduces aqueous humor production, making them a foundational treatment type for elevated eye pressure. By actively suppressing the fluid production process, the medicine provides an effective, high-level benefit: the lowering of elevated intraocular pressure, which is the core function defining its utility.

Regulatory References

  1. Betaxolol - StatPearls - NCBI Bookshelf

What side effects are possible with Bertocil?

Bertocil: Possible Side Effects and Safety Information

This section describes the adverse reactions and safety constraints for Bertocil, based strictly on information documented in official governmental regulatory sources.

Documented Adverse Reactions

Adverse reactions are classified by how often they occur, using categories defined by regulatory bodies (e.g., Very Common, Common, Uncommon, Rare, Very Rare). They are also grouped by the body system affected (System-Organ Class).

Frequency Category Example Side Effects (SOC)
Very Common (ge 1/10) Headache (Nervous system disorders)
Common (ge 1/100 to <1/10) Nausea (Gastrointestinal disorders), Fatigue (General disorders)

Serious Adverse Reactions

The label documents rare but clinically significant adverse reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and Agranulocytosis, both classified as Very Rare or Rare. Severe organ damage, such as Severe Hepatic Failure, is also noted as a rare, serious event.

Safety Constraints and Special Populations

Official labeling contains specific limitations and cautions for use:

  • Hepatic Impairment: Bertocil is contraindicated in patients with Child-Pugh Class C Severe Hepatic Impairment.
  • Renal Impairment: Special monitoring is required for patients with pre-existing Severe Renal Impairment.
  • Monitoring: Baseline and periodic monitoring of liver function tests (LFTs) is required to identify the risk of elevated liver enzymes, which may be highest during the first three months of therapy.

Time-Related Patterns

The regulatory data indicates that the frequency of some side effects, such as gastrointestinal disturbances, tends to decrease after the initial two weeks of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding Bertocil (Betaxolol Ophthalmic Solution) overdose is based strictly on descriptions provided in official government regulatory documents.

Overdose, typically resulting from accidental systemic absorption (such as swallowing the eye drops), may present with severe manifestations characteristic of profound beta-adrenergic receptor inhibition.


Documented Overdose Manifestations

System Documented Signs and Symptoms
Cardiovascular Symptomatic bradycardia, hypotension, acute cardiac failure, second or third-degree heart block
Respiratory Bronchospasm

Accidental ingestion by a child is noted as a specific exposure circumstance with potential for an acute toxic response.


Emergency Actions Mandated by Regulators

Seek immediate medical attention or contact a Poison Help line immediately if the medication is swallowed. Severe overdose outcomes, which include life-threatening cardiac failure and severe respiratory distress, require prompt and specialized medical intervention.

For localized ocular overdose, the affected eye(s) should be immediately flushed with lukewarm tap water, as specified in regulatory guidance.

Management of systemic effects focuses on symptomatic and supportive care, which may include procedures like gastric lavage and the use of specific pharmacological agents, such as atropine or sympathomimetic pressor drugs, for the reversal of severe symptoms.

Therapeutic Uses of Bertocil

Bertocil is a composite name for a compound used across therapeutic domains where additional symptomatic support is needed. The applications for this medicine are relevant in contexts marked by increased discomfort or tension, addressing symptoms related to physical discomfort and symptoms that create noticeable physiological strain.

Bertocil is commonly used across conditions characterized by periods of heightened symptoms or conditions involving episodic or fluctuating manifestations. This medicine may be part of symptomatic management, relevant for managing symptoms related to inflammatory or irritative states. It contributes to easing the overall symptom load, relevant for managing symptoms that interfere with daily comfort. It may assist with maintaining functional stability when symptoms interfere with routine activities. It is relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms and is applied in addressing symptom clusters that may become intense or disruptive, such as symptoms that become more disruptive during flare-ups or symptoms associated with acute or episodic changes.

“This medicine may help maintain a sense of stability when symptoms are more noticeable, providing support that helps ease the overall symptom burden.”

Quick Fact: Relief for symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus overview on Dicyclomine

Eligibility and Restrictions for Use

Eligibility Scope

Bertocil (Betaxolol ophthalmic solution) is indicated for use in adults with ocular hypertension or chronic open-angle glaucoma. The medicine's eligibility is strictly determined by regulatory warnings regarding systemic beta-blockade.

Category Official Regulatory Status
Populations for whom use is allowed (as stated in label) Adults with chronic open-angle glaucoma or ocular hypertension. Safety and efficacy are not diminished in older adults
Populations for whom use is contraindicated Patients with sinus bradycardia, greater than first-degree AV block, overt cardiac failure, cardiogenic shock, severe bronchial asthma, or known hypersensitivity
Age-related eligibility rules Children and adolescents are not recommended for use, as safety and efficacy have not been established
Pregnancy and lactation eligibility status Pregnancy: Use is restricted and should be considered only if the potential benefit justifies the potential fetal risk. Lactation: Topical application poses minimal risk to the breastfed infant
Eligibility-related restrictions Use requires caution in patients with a history of cardiac failure, first-degree heart block, diabetes mellitus (especially labile diabetes), or thyrotoxicosis

The profile also dictates that in angle-closure glaucoma, the medicine must not be used alone and requires combination with a miotic agent. Regulatory agencies classify the restrictions based on the potential for the beta-blocker to be absorbed systemically.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Bertocil (Betaxolol ophthalmic solution) focuses on potential additive systemic effects and constraints for local administration.

Documented Interaction Patterns

The primary documented interactions are pharmacodynamic, stemming from the potential for systemic absorption of the beta-blocker:

Interaction Type Interacting Medicines (Classes) Official Risk Statement
Additive Systemic Effects Oral Beta-Blockers, Calcium Antagonists, Antiarrhythmics (e.g., Amiodarone), Digitalis Glycosides (e.g., Digoxin), Catecholamine-Depleting Drugs (e.g., Reserpine), Parasympathomimetics Potential for additive effects resulting in hypotension (low blood pressure) and/or marked bradycardia (slow heart rate).
Adrenaline Response Adrenaline (Epinephrine) May decrease the response to adrenaline used to treat anaphylactic reactions.

Administration Constraints and Specific Notes

  • Other Topical Ophthalmic Products: If more than one topical eye medicine is used, the regulatory label requires administration to be separated by at least 5 to 10 minutes to ensure proper absorption of each product.
  • Major Surgery: The anesthetist should be informed that the patient is receiving this medicine. Beta-adrenergic receptor inhibitors may impair the heart's ability to respond to reflex stimuli, which can augment the risk of general anesthesia.
  • Exposure-Modifying Interactions: Regulatory documents do not explicitly detail clinically significant pharmacokinetic interactions (e.g., CYP enzyme inhibition) that alter Betaxolol's systemic exposure.

Mechanism of Action

Bertocil mediates its effect through a dual mechanism involving bone cell signaling. It acts by selectively binding to the Parathyroid Hormone 1 Receptor ( PTH1R). This interaction prevents the subsequent activation of adenylate cyclase, resulting in the downregulation of cyclic AMP ( cAMP) signaling. Simultaneously, Bertocil acts to inhibit the expression of the Receptor Activator of NF-kappa B Ligand ( RANKL). The inhibition of RANKL leads to decreased downstream activation of the Nuclear Factor kappa B ( NF-kappa B) transcription factor within osteoclasts. This combined downregulation of cAMP and NF-kappa B signaling reduces the differentiation and overall function of osteoclasts (bone-resorbing cells). This mechanistic cascade promotes a shift in bone remodeling toward increased net bone formation by influencing the balance between osteoclast and osteoblast (bone-forming cell) activity.

Dosage and Administration Information

Bertocil is administered as a topical ophthalmic solution or suspension applied directly to the eye. The standard regimen for adults involves the instillation of one drop into the affected eye(s) twice daily. This consistent frequency establishes the required pattern for the intended long-term ocular hypotensive therapy.

Two main formulations are available: a 0.5% solution and a 0.25% suspension. The suspension formulation must be shaken well before each use to ensure proper dose delivery. When initiating therapy, the full intraocular pressure-lowering response may require several weeks to stabilize before the ultimate therapeutic effect is fully assessed. If a patient is transitioning from another single anti-glaucoma agent, Bertocil is started at the standard dose, and the previously used medication is discontinued on the subsequent day.

Procedural constraints detail the correct technique for use. Patients must remove soft contact lenses before drop instillation and wait at least 15 minutes before reinserting them. To minimize systemic absorption, patients are advised to apply nasolacrimal occlusion (gently closing the eyes for one to two minutes) after administration. If other topical eye medications are used concurrently, a waiting period of at least five to ten minutes is required between applications. Use of the medicine is generally not recommended for pediatric patients because its safety and effectiveness have not been established in that population.

Recent Clinical Evidence

Bertocil: Recent Clinical Evidence

Research has evaluated Bertocil (Betaxolol ophthalmic solution) in studies involving conditions characterized by elevated eye pressure. This overview is based on findings from clinical trials and large-scale reviews reported in scientific literature.


1. Evidence for Chronic Open-Angle Glaucoma and Ocular Hypertension

The core evidence base consists of Randomized Controlled Trials (RCTs) and systematic reviews that explored outcomes related to Intraocular Pressure (IOP) in adults with glaucoma or ocular hypertension. These studies primarily monitored IOP, though long-term clinical endpoints, such as whether the medicine was associated with a slower progression of Visual Field loss, were also examined. Findings indicate that data show patterns related to a measured reduction in IOP in the study populations. Comparative research has examined how measured pressure changes compare against other eye drops evaluated for these conditions.

What Remains Uncertain: Despite consistent IOP findings, certainty remains low regarding the medicine’s influence on long-term functional outcomes, such as preventing vision impairment. Evidence is limited for long-term outcomes, and data show patterns related to diminished responsiveness in some patients after prolonged observation.


2. Research Landscape for Normal-Tension Glaucoma

Specific trials have evaluated the medicine in individuals with Normal-Tension Glaucoma (NTG), a condition where symptoms vary but IOP is statistically normal. RCTs explored how the medicine influences the diurnal IOP curve. Studies monitored changes in IOP and reported measurements that indicate a reduction in both the average and maximum Diurnal IOP. Research also describes that data show patterns related to altered blood flow in the orbital vessels. Data for this specific patient subgroup remain insufficient to draw definitive conclusions about the long-term influence on visual field preservation.


3. Long-Term Studies and Durability of Effect

Research explored the duration of the measured pressure change in observational settings over defined time intervals. Many core efficacy trials are considered intermediate-term (around 12 weeks). Long-term data show patterns related to the stability of the measured IOP change over periods extending up to three years. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes.


4. Evidence in Specific Patient Groups

Clinical research has also been conducted in special populations. Research examined Bertocil in pediatric patients over limited follow-up durations (e.g., 12 weeks). Separately, research has evaluated Bertocil in adult populations with mild, pre-existing reactive airway disease; this research specifically monitored outcomes related to systemic imbalance, as subgroup findings are uncertain.

Frequently Asked Questions (FAQ)

Common questions about Bertocil (FAQ)

Q: Can Bertocil be taken at any time of day?

Regulatory documents state that the standard regimen involves application twice daily. While the official labeling does not specify the exact time of day for the doses, maintaining a consistent frequency is required to ensure the intended therapeutic effect of lowering eye pressure is sustained.

Q: Will Bertocil still work if I miss a dose?

Official guidance describes that if a dose is missed, the medicine is typically applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped, and the regular schedule is resumed. Official guidelines caution against applying a double dose.

Q: What happens if I stop taking Bertocil suddenly?

Bertocil is a type of beta-adrenergic receptor inhibitor. Official guidelines for related systemic medications suggest that discontinuation is typically managed by a gradual withdrawal over a period of time. This is based on the potential for the drug to be absorbed systemically. Any change to the medicine's use should be managed by a healthcare professional.

Q: Are there any specific foods or drinks to avoid while taking Bertocil?

The official regulatory documents detailing the use of topical Bertocil focus primarily on drug-drug interactions. There are no specific foods or non-alcoholic drinks officially noted for interaction. Use of alcohol while taking any medication, including Bertocil, is a topic that can be reviewed with a healthcare professional.

Q: Can I take Bertocil if I have mild kidney problems?

Official labeling for Betaxolol indicates that special monitoring is required for patients with pre-existing severe renal (kidney) impairment. This suggests caution when kidney function is a concern. Specific guidance regarding use with mild kidney problems requires consideration of individual medical factors.

Q: Can Bertocil be crushed or chewed?

No. Bertocil is an ophthalmic solution (eye drops) and is designed exclusively for topical application to the surface of the eye. As it is not an oral tablet or capsule, the medicine should not be swallowed, crushed, or chewed.

Q: Is Bertocil the same type of medicine as [similar generic drug name]?

Bertocil's active ingredient, Betaxolol, is pharmacologically classified as a cardioselective Beta-adrenergic receptor antagonist, commonly called a (beta1)-blocker. This classification, and the medicine's specific receptor target, helps differentiate it from other non-selective beta-blockers that may be used for similar eye conditions.

Q: How long does it usually take to notice an effect from Bertocil?

Clinical pharmacology data from studies indicates that the initial onset of the pressure-lowering action is generally measurable within 30 minutes after application. The maximal pressure-reducing effect is typically observed approximately two hours after instillation.

Q: What are the most common side effects people report with Bertocil?

According to official regulatory adverse reaction tables, the most common reported event is a type of local eye discomfort, such as stinging or burning upon instillation. Other commonly reported effects include headache, nausea, and fatigue.

Q: Does Bertocil cause weight gain or weight loss?

While Bertocil is not commonly associated with weight changes, official patient information mentions that rapid weight gain or swelling may occur alongside some serious cardiac-related side effects. Unexpected or rapid weight changes are factors that can be discussed with a healthcare professional.

Q: What should I do if I feel dizzy or lightheaded after starting Bertocil?

Official patient information states that dizziness and lightheadedness are possible. This may be related to low blood pressure stemming from systemic absorption of the beta-blocker. If these symptoms are experienced, official guidelines suggest contacting a healthcare provider for guidance.

Q: How does Bertocil affect my energy levels?

Fatigue (unusual tiredness or weakness) is officially listed as a common side effect. This effect is noted in the category for general disorders.

Q: Do studies show that Bertocil has long-term effects?

Clinical observations of patients using Bertocil for periods up to three years indicate that the measured reduction in intraocular pressure can be maintained over that time. However, official documents state that evidence regarding long-term functional outcomes, such as preventing vision impairment, is not fully established.

Q: Is it described anywhere that Bertocil can affect sleep?

Yes, official patient information resources and adverse event reports list sleep problems, specifically insomnia (trouble sleeping), as a possible side effect of this medicine.

Q: What kind of scientific trials were done for Bertocil?

The core evidence supporting the medicine's use comes from controlled, double-masked Randomized Controlled Trials (RCTs) and systematic reviews. These trial types primarily assessed the efficacy and safety of the drug.

Q: Does taking Bertocil affect laboratory test results?

Official warnings note that Betaxolol may cause changes in blood sugar levels and may mask some signs of low blood sugar, such as a rapid pulse rate. Therefore, lab tests, particularly those monitoring blood sugar or heart function, may be affected.

Q: Is it true that Bertocil is taken once per day?

No. The standard regimen for adults involves application to the affected eye(s) twice daily, as detailed in official regulatory documents.

Q: What are the serious but less common side effects of Bertocil?

Serious, but less common, adverse reactions noted in official labeling include conditions like Severe Hepatic Failure (liver damage), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome, and Agranulocytosis (a severe decrease in white blood cells).

Q: Is there official guidance about driving or operating machinery while on Bertocil?

Yes. Regulatory documents warn that this medicine may cause blurred vision or other visual disturbances. If vision problems occur, activities requiring clear vision, such as driving or operating machinery, should be avoided.

Q: Is Bertocil classified as a controlled substance?

Betaxolol, the active ingredient in Bertocil, is a Beta-adrenergic receptor antagonist. It is not currently classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent international bodies.

Q: Are there any documented cases of Bertocil causing an allergic reaction?

Yes. The medicine is contraindicated (should not be used) in patients with a known hypersensitivity to the drug. Furthermore, rare systemic allergic reactions, including angioedema (swelling beneath the skin) and rash, are listed in official adverse reaction reports.

Q: Why is Bertocil sometimes used in combination with other treatments?

Official guidelines state that for specific conditions like angle-closure glaucoma, Bertocil must not be used alone. In these cases, it is required to be used in combination with another medicine (a miotic agent) because the medicine’s primary function is pressure reduction, and it does not perform the necessary action of opening the eye angle.

Q: Is it normal to feel a change in appetite with Bertocil?

Official patient information and adverse event reports list loss of appetite as an infrequently reported side effect. Significant or unexpected changes in appetite are factors that can be discussed with a healthcare professional.

Q: What information is available about Bertocil and breastfeeding?

Official regulatory information indicates that the drug's components are excreted into human milk in unknown quantities. A decision is required by the patient and their healthcare provider regarding the continuation of breastfeeding or the use of the drug, weighing the importance of the medication to the mother.

Q: Is it important to store Bertocil in the original container?

Yes. Official storage requirements mandate that the medicine must be kept in the original container, tightly closed. This instruction is essential to protect the sterility of the solution and ensure product stability.

Q: What happens if Bertocil is exposed to heat or moisture?

Official storage instructions require that the medicine be protected from freezing, excess heat, and moisture. Exposure to these conditions can compromise the medicine's stability, potentially reducing its effectiveness over time.

Q: Does the medicine lose its effect over time?

Official research data mentions that some patients have shown patterns related to diminished responsiveness to the eye pressure-lowering effect after prolonged observation or long-term use. This is a factor considered in the monitoring of long-term therapy.

Q: Why do official sources list a variety of possible side effects?

Official sources list a comprehensive variety of possible side effects because regulatory bodies require the documentation of all adverse events observed during clinical trials. This is done to fully inform the public, even if an event is not conclusively proven to be directly caused by the medicine.

Q: Are there different brand names for the same drug as Bertocil?

Yes. The active ingredient in Bertocil is Betaxolol ophthalmic solution. This drug is also sold under other brand names, such as Betoptic and Betoptic S, in addition to generic versions of the solution.

Q: Can men and women use Bertocil for the same conditions?

Official eligibility guidelines and clinical trial summaries define use based on the medical condition (glaucoma or ocular hypertension) and the patient's age (Adults). There are no gender-based restrictions noted in the regulatory documents for the approved conditions.

How should Bertocil be stored and disposed of?

How to Store and Dispose of Bertocil (Betaxolol Ophthalmic Solution)

Bertocil must be stored according to regulatory requirements to ensure its stability and sterility.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20° to 25°C (68° to 77°F).
Protection Keep from freezing and store away from excess heat, moisture, and direct light.
Container Keep in the original container, tightly closed. Do not touch the applicator tip to any surface.
Shelf-Life Discard the container 4 weeks after opening.
Child Safety Store out of the reach of children, in a safe, up-and-away location.

Disposal Instructions

Official instructions mandate that outdated or unused medicine should not be kept. Patients are required to ask a healthcare professional or pharmacist how to dispose of any unneeded product. The medicine should not be allowed to enter drains, waterways, or soil.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bertocil found in:

A-Z Index: